GLP-1s Show 24% Kidney Benefit and Broader Organ Gains Beyond 15% to 21% Weight Loss
Updated
Updated · Forbes · Aug 8
GLP-1s Show 24% Kidney Benefit and Broader Organ Gains Beyond 15% to 21% Weight Loss
3 articles · Updated · Forbes · Aug 8
Summary
Randomized trials are recasting GLP-1 drugs as multi-organ therapies, with semaglutide cutting major kidney outcomes 24% in the 3,533-patient FLOW study and tirzepatide improving obstructive sleep apnea measures in SURMOUNT-OSA.
72-week ESSENCE data showed 62.9% of semaglutide patients achieved MASH resolution without worsening fibrosis, versus 34.3% on placebo, extending the class’s benefits to liver disease.
Observational evidence also points to effects in the brain and blood vessels: a BMJ study of 606,434 veterans linked GLP-1 use to a 14% lower substance-use-disorder risk, while a matched study found a 31% lower pulmonary embolism risk.
Nearly 2 million veterans in a Nature Medicine atlas showed associations with lower risks across neurocognitive, psychiatric, coagulation and infectious outcomes, though such real-world signals do not prove causation.
About 1 in 8 U.S. adults has tried a GLP-1 and 6% currently use one, a scale that could pressure insurers to view roughly $1,000-a-month drugs as prevention against far costlier events like stroke ICU stays or liver transplants.
If GLP-1 drugs rewrite the brain's reward system to reject alcohol, how will this medical breakthrough disrupt industries relying on our social drinking habits?
Could the unexpected side effect of popular weight-loss injections accidentally cure addiction, or will it permanently erase our ability to experience everyday pleasures?
Are patients secretly risking severe organ damage by forcing themselves to drink through the intense nausea caused by modern weight-loss injections?